Core Viewpoint - The controversy surrounding Giant Bio's product "Recombinant Collagen Essence" has raised questions about its collagen content, leading to a significant decline in the company's stock price following allegations of false labeling and exaggerated claims [1][6]. Group 1: Product Allegations - Beauty blogger "Big Mouth Doctor" (Hao Yu) reported that the collagen content in Giant Bio's "Recombinant Collagen Essence" was only 0.0177%, which is below the national standard of 0.1% for non-trace components [1]. - The report also indicated that the core amino acid "glycine," essential for collagen, was not detected in the product, suggesting potential false labeling and exaggeration of claims [1]. Group 2: Company Response - In response to the allegations, Giant Bio issued a statement denying the claims, asserting that multiple self-test results showed collagen content greater than 0.1%, contradicting the reported data [1]. - The company emphasized that its testing methods adhered to the "Pharmacopoeia of the People's Republic of China" and industry standards, and it has commissioned a third-party organization for retesting [1]. Group 3: Stock Market Impact - Following the allegations, Giant Bio's stock price experienced a continuous decline over four days, indicating a significant market reaction to the controversy [6]. - The situation was exacerbated by a lengthy article from Huaxi Bio, which criticized Giant Bio's marketing strategies and its comparison of collagen to hyaluronic acid [8]. Group 4: Connections and Recommendations - There are notable connections between Huaxi Bio and Big Mouth Doctor, as both have indirect stakes in Shanghai Liuye Medical Technology Service Co., Ltd., suggesting potential conflicts of interest [8]. - Big Mouth Doctor has previously recommended products from Huaxi Bio, indicating a possible bias in the ongoing criticism of Giant Bio [9].

Core Viewpoint - The article discusses the revolutionary changes occurring in the beauty industry due to the intersection of synthetic biology and artificial intelligence (AI), highlighting the rapid advancements made by Chinese company Weiming Shiguang in this field [2][4]. Group 1: Company Overview - Weiming Shiguang, established in 2021, focuses on the innovative research and production of bioactive materials, leveraging AI and synthetic biology to enhance efficiency and sustainability in beauty ingredient development [8][24]. - The company has completed five rounds of financing within four years, attracting significant investments from major players like L'Oréal and Naissance Group, indicating strong market confidence in its innovative capabilities [4][9]. Group 2: Technological Innovations - Weiming Shiguang has built a comprehensive research and development system that integrates AI across three main areas: ingredient discovery, evaluation, and sustainable production, enabling end-to-end innovation in ingredient production [11][20]. - The company boasts the world's largest database of 30 billion bioactive molecules, significantly improving the efficiency of targeted screening by over 10,000 times through AI algorithms [15][21]. Group 3: Strategic Partnerships - The strategic partnership between Weiming Shiguang and L'Oréal aims to advance the development of bioactive ingredients and sustainable beauty solutions, showcasing a deep integration of science and innovation [6][9]. - Weiming Shiguang's recognition in L'Oréal's "BIG BANG" beauty technology co-creation program highlights its innovative approach and alignment with global sustainability goals [8][9]. Group 4: Market Position and Global Expansion - The company is positioning itself as a key player in the global beauty ingredient market, having established partnerships with several leading brands and manufacturers, thus enhancing its international presence [28][29]. - Weiming Shiguang is actively building an international team and compliance framework to support its global expansion, aiming to elevate Chinese beauty ingredients to the global stage [28][29].

临近年中电商大促，"重组胶原蛋白第一股"巨子生物却陷入巨大争议。 近日，一位自称为香港大学化学博士、前欧莱雅中国科学传播负责人的社交媒体博主"大嘴博士"连续发 文称，经检测，巨子生物旗下品牌可复美的核心产品"胶原棒（Human-Like重组胶原蛋白肌御修护次抛 精华）"中的重组胶原蛋白实际含量低于宣传口径。 作为巨子生物的收入王牌，可复美系列在2024年大赚45亿元、同比增长62.9%，占公司总收入的80%。 其中，以"胶原棒"为核心的功效型护肤品品类又为可复美贡献了近八成的收入。 在小红书等社交媒体上，不少质疑声因此认为，如果连头部企业都可能存在"造假"现象，作为普通消费 者，还能不能何信任和选择重组胶原蛋白产品？ 重组胶原用得少，是"产量跟不上"？ 最初的争议源于一组数字。 按照"大嘴博士"选择的高精度HPLC高效液相色谱氨基酸定量检测法，"胶原棒"中的重组胶原蛋白实际 含量仅为0.0177%，远低于产品中标注的"成分"添加（≥0.1%），或构成配方表造假。对此，可复美则 表示，按照国内重组胶原蛋白辅料"YY/T 1947-2025"行业标准，多批次产品检测结果的胶原蛋白含量均 大于0.1%。 双方随后的 ...

Core Viewpoint - The public relations battle between Huaxi Biological and Juzhi Biological has led to a significant market value loss for Juzhi Biological, amounting to 17.4 billion yuan in just 10 days [4]. Group 1: Public Relations Battle - Huaxi Biological publicly criticized the capital market's behavior of favoring collagen while disparaging hyaluronic acid, directly naming Juzhi Biological and several brokerage firms [3][4]. - Juzhi Biological's market value dropped from 90.9 billion yuan to 73.5 billion yuan within 10 days, a decrease of 17.4 billion yuan [4]. - The negative publicity may impact consumer sentiment and Juzhi Biological's performance during the upcoming 618 promotional event [4]. Group 2: Controversial Testing Methods - The primary controversy revolves around the testing methods used to assess the collagen content in Juzhi Biological's products [5][6]. - A beauty blogger claimed that the actual collagen content in Juzhi Biological's product was only 0.0177%, significantly below the stated standard of ≥0.1% [9]. - Juzhi Biological defended its testing methods, stating that the blogger's approach lacked industry standards and that they were involved in formulating these standards [11]. Group 3: Timeline of Events - On May 17, Huaxi Biological published a critical article targeting Juzhi Biological and brokerage firms [18]. - Juzhi Biological did not respond initially, leading to perceptions of a "pillow fight" in the public relations battle [18]. - The timeline of events suggests a coordinated effort by the blogger to raise questions about Juzhi Biological's products, particularly before the 618 sales event [22][23]. Group 4: Industry Implications - The incident serves as a cautionary tale for other beauty and skincare brands regarding the importance of protecting their core assets, particularly product ingredients and their efficacy [33]. - Companies are urged to establish robust standards and testing methods to safeguard against potential public relations crises [34]. - The need for a credible third-party testing framework is emphasized, as the absence of such standards can lead to consumer distrust and brand damage [30].

证券代码：688363 证券简称：华熙生物 华熙生物科技股份有限公司 2024 年年度股东大会会议资料 华熙生物科技股份有限公司 2024 年年度股东大会会议资料 华熙生物科技股份有限公司 2024 年年度股东大会会议资料 华熙生物科技股份有限公司 为保障华熙生物科技股份有限公司（以下简称"公司"）全体股东的合法权 益，维护股东大会的正常秩序，保证股东大会的议事效率，确保本次股东大会如 期、顺利召开，根据《中华人民共和国公司法》《华熙生物科技股份有限公司章 程》《华熙生物科技股份有限公司股东大会议事规则》等相关规定，特制定公司 一、为保证股东大会的有序进行，切实维护股东的合法权益，现场出席会议 的股东及股东代理人需进行会议登记，以核实股东资格。会议开始后，现场会议 登记将终止，会议主持人将宣布现场出席会议的股东和代理人人数及所持有表决 权的股份总数。为了顺利参加股东大会，建议股东提前半小时到达会议现场，并 按规定出示会议登记所需资料办理会议登记。 二、为保证股东大会的正常秩序，除出席会议的股东及股东代理人、公司董 事、监事、高级管理人员、公司聘请的律师及董事会邀请的其他人员外，公司有 权拒绝其他无关人员进入会 ...

华熙生物科技股份有限公司 2024年年度股东大会会议资料 证券代码：688363 证券简称：华熙生物 2024 年年度股东大会会议资料 2025 年 6 月 华熙生物科技股份有限公司 2024年年度股东大会会议资料 2024 年年度股东大会会议资料目录 | 华熙生物科技股份有限公司 年年度股东大会会议须知 2024 | | | 2 | | --- | --- | --- | --- | | 华熙生物科技股份有限公司 | 年年度股东大会会议议程 2024 | | 4 | | 议案一 | 关于审议公司 年年度报告及其摘要的议案 2024 | | 6 | | 议案二 | 关于审议 年度董事会工作报告的议案 2024 | | 7 | | 议案三 | 关于审议 年度监事会工作报告的议案 2024 | | 18 | | 议案四 | 关于 2025 年度公司董事、监事薪酬方案的议案 | | 23 | | 议案五 | 关于公司 2024 年度财务决算报告的议案 | | 24 | | 议案六 | 关于公司 2024 年度利润分配预案的议案 | | 33 | | 议案七 | 关于取消监事会、修订《公司章程》并办理工商变更登记的议 ...

"2020年1月启动研发，2022年6月启动国内关键Ⅰ期临床研究，2023年1月向国家药品监督管理局递 交创新药上市申请，该药品历时5年终于上市。"山东盛迪医药制剂研究所负责人郭创龙介绍，瑞格列汀 是中国首个自主研发的二肽基肽酶-4抑制剂类药品，二甲双胍则是常见降糖药，两者作用方式不同，很 多患者需同时服用。"而瑞格列汀二甲双胍片是两种单药的复方制剂，患者以后只需要服用这一种药即 可，减轻了患者服药负担。"郭创龙介绍。 该药品的上市，标志着山东盛迪医药有限公司在创新药研发领域取得重要突破。 又一1类创新药获批上市 济南现代医药产业动能澎湃 5月22日，国家药品监督管理局（NMPA）官网显示，山东盛迪医药有限公司申报的1类创新药瑞格 列汀二甲双胍片（I）/（II）（瑞霖唐）获批上市。这是该公司获批的首个1类创新药，也是济南第4款 创新药，将造福糖尿病患者。 糖尿病已经成为继肿瘤、心脑血管病之后，第三位严重危害人类健康的慢性疾病。该药品正是用于 治疗成人2型糖尿病的。 创新药陆续上市的背后，是近年来济南市大力发展现代医药产业的结果。 现代医药是济南市13条标志性产业链之一。近年来，该市先后出台多个政策文件支撑产业 ...

Investment Rating - The report maintains a "Positive" outlook on international cosmetics and medical beauty companies for Q1 2025 [2]. Core Insights - The global beauty market is projected to grow at a rate of 4.5% in 2024, a decline from the 8% growth seen in 2023, with significant regional disparities [3][12]. - The North Asia market, particularly China, has shown signs of improvement, but overall performance remains subdued, with North America exhibiting signs of fatigue [3][12]. - International beauty groups are still grappling with performance declines or slower growth, which may become the new normal due to various factors including the pandemic and macroeconomic conditions [3][15]. - Companies are adopting localization strategies and investing in local brands to maintain market share amid fierce competition from domestic brands [3][19]. Summary by Sections 1. Global Beauty Market Trends - The beauty market continues a stable trend from 2024, with Europe outperforming other regions at a 7.5% growth, while North Asia has seen a 2% decline [3][12]. - The international beauty groups are facing a challenging environment with performance fluctuations and strategic adjustments [15]. 2. L'Oréal Performance - L'Oréal's Q1 2025 revenue growth slowed to 4.4%, with the Chinese market remaining flat and tourism retail channels under pressure [3][27]. - The company is actively investing in local brands and expanding its product matrix to compete with domestic brands [3][27]. 3. Estée Lauder Performance - Estée Lauder reported a 9.9% decline in revenue for Q1 2025, continuing a trend of three consecutive quarters of revenue decline [3][51]. - The company is undergoing strategic reforms to address issues related to brand and product positioning [47][51]. 4. Shiseido Performance - Shiseido's revenue decreased by 8.5% in Q1 2025, with its main brand struggling while the ELIXIR brand showed growth [3][18]. - The company is focusing on strategic product launches and price adjustments to enhance profitability [3][27]. 5. Investment Recommendations - Recommended companies include Up Beauty and Proya for their strong brand matrices and growth potential, as well as Marubi for leveraging Douyin traffic [4]. - In the medical beauty sector, companies with strong R&D capabilities and broad product pipelines, such as Aimeike, are highlighted as key investment opportunities [4].

Core Viewpoint - The domestic medical beauty industry is facing significant scrutiny due to allegations regarding the quality and labeling of collagen products, particularly targeting the leading company, Giant Bio, and its flagship product, "Collagen Stick" [1][5][6]. Industry Overview - The controversy highlights the lack of national standards for the testing of recombinant collagen in cosmetics, leading to significant discrepancies in test results as companies rely on self-defined methods or pharmaceutical industry standards [5][6]. - The National Medical Products Administration has initiated the establishment of industry standards for recombinant collagen and its testing methods, with companies participating in the process [5]. Company-Specific Issues - Giant Bio's "Collagen Stick" was accused of having a collagen content of only 0.0177%, which is below the national cosmetic labeling requirement of 0.1% for non-trace additives, and the key amino acid glycine was reportedly not detected [6][8]. - In response to the allegations, Giant Bio issued a statement denying the claims, asserting that their products meet the required standards and have been approved by regulatory authorities [8]. Testing Method Discrepancies - The testing methods used by the parties involved differ significantly; the blogger employed a high-precision HPLC method, while Giant Bio referenced outdated national standards that have been criticized for their ineffectiveness in the current complex cosmetic landscape [9][10]. - The HPLC method is noted for its high sensitivity and ability to accurately quantify amino acids, while the methods referenced by Giant Bio have been deemed inadequate for testing collagen in cosmetics [10][15]. Market Impact - Following the allegations, Giant Bio's stock price fell over 8% on the Hong Kong Stock Exchange, closing down 4.04%, reflecting market concerns over the credibility of its products [8].

Core Viewpoint - The controversy surrounding Juzhibio's flagship product, the "Recombinant Collagen Essence," has raised significant concerns about its actual collagen content and potential false advertising, leading to a sharp decline in its stock price and questioning the company's marketing practices [1][3]. Group 1: Product Controversy - A report by the self-media "Big Mouth Doctor" claims that the actual recombinant collagen content in Juzhibio's "Recombinant Collagen Essence" is only 0.0177%, which is below the cosmetic labeling standard of 0.1% [2][3]. - The report also highlights the absence of glycine, a key structural component of collagen, challenging the product's technical authenticity [2]. - Juzhibio has denied these claims, asserting that internal tests show collagen content greater than 0.1% and questioning the validity of the testing methods used by the "Big Mouth Doctor" team [3]. Group 2: Financial Performance and Dependency - Juzhibio's revenue is heavily reliant on its skincare products, with 99.7% of revenue coming from this segment, while health products contribute only 0.3% [5]. - The "Recombinant Collagen" and "Keli Jin" brands account for over 90% of the company's revenue, indicating a significant dependency on these two brands [6][7]. - In 2024, Juzhibio's sales and distribution expenses are projected to be 2.008 billion yuan, while R&D expenses are only 106 million yuan, highlighting a 19-fold disparity [7]. Group 3: Market Impact - Following the allegations, Juzhibio's stock price fell by 8% after the market opened on May 26 [3]. - The affected product has been removed from all sales channels, including major platforms like Taobao, Douyin, and JD [3]. - If consumer backlash leads to collective lawsuits or mass returns, it could severely impact the company's sales performance during key promotional periods, jeopardizing its annual revenue growth targets [6].